Fighting Evolution 3: The Evolution of Intravitreal Injection in Ophthalmology

Intravitreal (IVT) injection has revolutionized the treatment of various eye conditions, including wet age-related macular degeneration and diabetic macular edema. Pharmaceutical companies have developed different drug administration techniques, including IVT injection, to combat these diseases. However, this invasive procedure requires technical expertise from healthcare professionals.

The development of IVT injection involved collecting ocular tissues and fluids, ophthalmology monitoring, and conducting nonclinical and clinical studies. Researchers identified potential side effects such as bleeding, retinal tear, cataracts, infection, uveitis, loss of vision, and increased ocular pressure. Despite these risks, IVT injection has become the mainstay for delivering drugs to treat conditions that affect the back of the eye.

The eye is a unique organ that has evolved various anatomic and immunological barriers to protect tissues lacking regenerative capacity and maintain a clear optic pathway essential to vision. In response, an international consortium for innovation and quality was established, along with an industry perspective on the nonclinical and early clinical development of intravitreal drugs.

The evolution of IVT injection highlights the importance of collaboration between pharmaceutical companies, healthcare professionals, and researchers in developing innovative treatments for eye diseases. By understanding the complexities of the eye and the potential risks associated with IVT injection, we can continue to improve treatment outcomes and fight against vision loss.

Fighting evolution 3